BlossomHill Therapeutics Inc(BLSM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 4 at 7:30 PM ET (Korea 9/5 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 30.03% | Shs Outstand | 30.6M | Perf Week | 12.53% |
| Market Cap | 0.67B | Forward P/E | - | EPS next Y | - | Insider Trans | 20.63% | Shs Float | 21.4M | Perf Month | - |
| Enterprise Value | 0.84B | PEG | - | EPS next Q | -0.93 | Inst Own | 17.7% | Short Float | 0.52% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 15.88% | Short Ratio | 0.38 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.11M | Perf YTD | 39.75% |
| Book/sh | -4.96 | P/C | 5.81 | EPS past 3/5Y | - | ROE | - | 52W High | 6.79% ($20.61) | Perf Year | - |
| Cash/sh | 3.79 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 44.33% ($15.25) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 8.01% - | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.37 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 77.05 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.37 | Sales Q/Q | - | SMA20 | 24.67% ($17.65) | Beta | - | Target Price | $32.2 |
| Payout | - | Debt/Eq | - | Earnings | 2026/06/03 | SMA50 | 25.23% ($17.58) | Rel Volume | 0.58 | Prev Close | $20.02 |
| Employees | 63 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | 25.23% ($17.58) | Avg Volume(3M) | 0.29M | Price | $22.01 |
| IPO | 2026/8/7 | Option/Short | No/Yes | Trades | 2795 | Volume | 168,088 | Change | 9.94% |
Company
BLSM is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US clinical-stage biotech company developing small-molecule oncology drugs based on chemistry-driven design. Founded in 2020 and headquartered in San Diego, California, the company is clinically validating drug candidates that target resistance issues of existing therapies in lung cancer and hematologic malignancies.
Over the past 1 year, on the higher side
0% below its 1-year high.
BLSM makes money exceptionally well
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 17.7%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $674M.
BLSM $674M PER -
VRTX $138B PER 31.8
REGN $85B PER 20.5
ARGX $65B PER 39.4
FAQ
What kind of company is BLSM?
BLSM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BLSM?
The market cap of BLSM is approximately $674M, ranking 3,005 within its sector.
What is the 52-week high and low for BLSM?
BLSM has recorded a 52-week high of $20.61 and a low of $15.25.
